Adamis Pharmaceuticals Corporation (ADMP) News

Adamis Pharmaceuticals Corporation (ADMP): $0.50

0.03 (+5.52%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter ADMP News Items

ADMP News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ADMP News Highlights

  • ADMP's 30 day story count now stands at 2.
  • Over the past 11 days, the trend for ADMP's stories per day has been choppy and unclear. It has oscillated between 1 and 1.

Latest ADMP News From Around the Web

Below are the latest news stories about Adamis Pharmaceuticals Corp that investors may wish to consider to help them evaluate ADMP as an investment opportunity.

Adamis Announces Inducement Option Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease, today announced that the compensation committee of the board of directors and the company’s independent directors approved the grant of stock options on February 15, 2022, to purchase an aggregate of 1

Yahoo | February 18, 2022

Adamis Pharmaceuticals Provides Enrollment Update of Subjects in Phase 2/3 Study of Tempol for the Treatment of COVID-19

SAN DIEGO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the enrollment and dosing of more than 100 subjects in the Company’s ongoing Phase 2/3 study of Tempol for the treatment of COVID-19. The Data Safety Monitoring Board (DSMB) will now examine clinical and safety data from the first 50 subjects as part of the first interim analysis. COVID-19 is a complex disease that manifests in multiple phases including, among others, viral replication

Yahoo | February 7, 2022

Adamis Pharma Updates 1 Key Risk Factor

3 clinical trial in patients affected by COVID-19. Importantly, Tempol has demonstrated antiviral, anti-inflammatory, and antioxidant activity. While there have been recent approvals for oral antiviral drugs, Adamis noted Tempol’s unique mechanism of action and safety profile would offer an unmet medical requirement. With this development in mind, let us take a look at the changes in Adamis’ key risk factors that investors should know.

Kailas Salunkhe on TipRanks | January 12, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Grab a cup of coffee and get ready for another busy day of trading as we start with the biggest pre-market stock movers for Tuesday!

William White on InvestorPlace | January 11, 2022

Thinking about buying stock in Pluristem Therapeutics, DiDi Global, Robinhood Markets, Bitfarms, or Adamis Pharmaceuticals?

NEW YORK , Jan. 10, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PSTI, DIDI, HOOD, BITF, and ADMP. Full story available on Benzinga.com

Benzinga | January 10, 2022

Adamis Pharmaceuticals Submits Fast Track Application to FDA for Tempol for the Treatment and Prevention of COVID-19

SAN DIEGO, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the submission of a Fast Track Application to the U.S. Food and Drug Administration (FDA) for Tempol for the treatment and prevention of COVID-19. Tempol is currently being studied in a Phase 2/3 clinical trial in adult patients with confirmed COVID-19 infection. Tempol has been shown to have antiviral, anti-inflammatory, and antioxidant activity. Although recent oral antiviral drugs ha

Yahoo | January 10, 2022

Is the Options Market Predicting a Spike in Adamis Pharmaceuticals (ADMP) Stock?

Investors need to pay close attention to Adamis Pharmaceuticals (ADMP) stock based on the movements in the options market lately.

Yahoo | December 20, 2021

Adamis Pharmaceuticals (NASDAQ:ADMP) Stock Crosses Below 200 Day Moving Average of $1.00

Adamis Pharmaceuticals Co. (NASDAQ:ADMP) crossed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $1.00 and traded as low as $0.62. Adamis Pharmaceuticals shares last traded at $0.65, with a volume of 1,022,765 shares. A number of equities analysts have weighed in []

Dakota Financial News | December 19, 2021

Adamis Pharmaceuticals (NASDAQ:ADMP) Raised to Hold at Zacks Investment Research

Zacks Investment Research upgraded shares of Adamis Pharmaceuticals (NASDAQ:ADMP) from a sell rating to a hold rating in a research note published on Friday morning, Zacks.com reports. According to Zacks, “Adamis Pharmaceuticals Corporation, formerly Cellegy Pharmaceuticals, Inc., is a specialty pharmaceutical company engaged engages in the research, development, and commercialization of prescription medicines for the […]

Transcript Daily | December 13, 2021

Adamis Pharmaceuticals (NASDAQ:ADMP) Shares Pass Below Two Hundred Day Moving Average of $1.00

Shares of Adamis Pharmaceuticals Co. (NASDAQ:ADMP) passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $1.00 and traded as low as $0.66. Adamis Pharmaceuticals shares last traded at $0.68, with a volume of 2,135,672 shares trading hands. Separately, Zacks Investment Research downgraded shares of Adamis []

Dakota Financial News | December 4, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4813 seconds.